Spoken Alpha
Inmune Bio, Inc.
Inmune Bio develops clinical-stage immunotherapy treatments designed to reprogram the innate immune system for inflammatory and oncologic diseases. The company's lead program, CORDStrom, is a cell therapy using pooled human umbilical cord-derived mesenchymal stromal cells to treat recessive dystrophic epidermolysis bullosa, a rare pediatric genetic disorder.
Inmune Bio, Inc is a Healthcare company operating in Biotechnology with a $61.6M market cap.
Most recent reported earnings: Q3 FY2026 (Oct 28, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for INMB.
$ curl https://api.spokenalpha.com/v1/companies/INMBFAQ
Spoken Alpha indexes INMB's earnings call transcripts at https://spokenalpha.com/companies/INMB. Each call links to attributed speakers and parsed analyst Q&A.
Inmune Bio, Inc. (INMB) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
Inmune Bio, Inc. (INMB) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-28 | — | $-0.18 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.05 | $-0.20 | +75.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.20 | $-0.18 | -11.1% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.18 | $-0.27 | +33.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-10-29 | $-0.24 | $-0.32 | +25.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.34 | $-0.37 | +8.1% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.43 | $-0.45 | +4.4% | $50.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.40 | $-0.54 | +25.9% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-10-30 | $-0.60 | $-0.49 | -22.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.50 | $-0.62 | +19.4% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.61 | $-0.52 | -17.3% | $14.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.47 | $-0.44 | -6.8% | $28.0K | — | — | EODHD |
| Q3 FY2023 | 2023-10-31 | $-0.48 | $-0.40 | -20.0% | $43.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.36 | $-0.38 | +5.3% | $46.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.36 | $-0.02 | -100.0% | $38.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-01 | $-0.32 | $-0.48 | +33.3% | $97.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-0.43 | $-0.52 | +17.3% | $98.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.38 | $-0.47 | +19.1% | $16.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.39 | $-0.60 | +35.0% | $163.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.55 | $-0.58 | +5.2% | $163.0K | — | — | EODHD |
Source: EODHD. INMB reported actuals as published; sparse fields render as —.